All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves Apellis Pharmaceuticals' C3 inhibitor Empaveli for broader use in C3 glomerulopathy and IC-MPGN
Protein therapy, autoimmune, complement inhibitor, C3 glomerulopathy, renal disease, pediatric indication - Read more

China’s NMPA approves Eisai's LENVIMA plus pembrolizumab and TACE for unresectable hepatocellular carcinoma following positive Ph3 results
Small molecule, cancer, antibody, hepatocellular carcinoma, combination therapy, tyrosine kinase inhibitor - Read more

THE GOOD
Business Development & Partnerships

Bristol Myers Squibb, Bain Capital form immune disease startup with five BMS drugs in $300M deal
Equity investment, spin-off, autoimmune, small molecule, milestone payments - Read more

Concept Life Sciences, Fios Genomics partner to enhance bioinformatics capabilities for drug discovery data analysis
Strategic partnership, data analytics, drug discovery, bioinformatics, R&D, global - Read more

ViroCell and AvenCell partner on retroviral vector manufacturing for allogeneic CAR-T therapies targeting blood cancers
Manufacturing agreement, cell therapy, oncology, autoimmune disease, manufacturing - Read more

LTZ Therapeutics, Eli Lilly partner on myeloid engager platform for autoimmune diseases; double-digit million upfront plus equity investment
Research collaboration, autoimmune disease, myeloid engager, milestone payments, equity investment - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Lilly's Jaypirca matches Imbruvica in Ph3 trial for BTK inhibitor-naïve chronic lymphocytic leukemia patients
Small molecule, cancer, BTK inhibitor, chronic lymphocytic leukemia, comparative efficacy, blood cancer - Read more

Aclaris Therapeutics' ATI-2138 ITK/JAK3 inhibitor shows positive Ph2a results in atopic dermatitis patients
Small molecule, autoimmune, kinase inhibitor, atopic dermatitis, alopecia areata, dual-targeted (ITK/JAK3) - Read more

Cardiff Oncology's onvansertib shows 19% improved response rate in Ph2 trial for RAS-mutated metastatic colorectal cancer
Small molecule, cancer, PLK1 inhibitor, colorectal cancer, RAS-mutation, combination therapy - Read more

Guardant Health's Ph3 RADIOHEAD study shows reveal detects immunotherapy failure months before standard imaging
Immunotherapy, cancer, liquid biopsy, minimal residual disease, ctDNA, treatment monitoring - Read more

THE GOOD
Earnings & Finances

AstraZeneca Q2 profits surge 27% to $2.4B, driven by 18% growth in cancer drug sales
Oncology therapeutics, cancer, financial, strategic, revenue impact - Read more

THE GOOD
Fundraises

Artbio raises $132M Series B for radiopharmaceutical cancer therapies and manufacturing
oncology, radiopharmaceuticals, cancer therapeutics, prostate cancer, manufacturing - Read more

Pahr Therapeutics raises $14M seed financing for novel pulmonary arterial hypertension treatments
Pulmonary arterial hypertension, cardiovascular, preclinical, drug discovery, platform-enabled - Read more

LIfT BioSciences secures €12M ($13.9M) grant for first-in-human trial of neutrophil immunotherapy for cancers
Oncology, cell therapy, immunotherapy, solid tumors, clinical-stage - Read more

Lobe Sciences raises $341,425 CAD ($248K) private placement for general corporate purposes and working capital
Rare disease, biopharmaceutical, underserved diseases - Read more

THE GOOD
Investments

WuXi Biologics begins construction of modular drug product facility in Singapore; operations expected by 2027
Biologics manufacturing, contract manufacturing, operational, strategic, facility expansion - Read more

THE GOOD
Mergers & Acquisitions

Bausch Health acquires Durect for $63M, gaining phase 3-ready liver drug with blockbuster potential
Small molecule, DNMT modulator, liver disease, strategic acquisition, major transaction - Read more

THE GOOD
Mergers & Acquisitions

Bausch Health acquires Durect for $63M, gaining phase 3-ready liver drug with blockbuster potential
Small molecule, DNMT modulator, liver disease, strategic acquisition, major transaction - Read more

THE GOOD
Politics & Policy

Senate Democrats investigate HHS Secretary Kennedy's firing of CDC's immunization advisory committee members
Vaccine policy, regulatory, governmental, public health, political - Read more

THE BAD
Clinical Trials

Merck & Co. halts Ph2 trials of MK-6194, an IL-2 mutein for vitiligo and systemic lupus erythematosus
Protein therapy, autoimmune, IL-2 mutein, lupus, vitiligo, regulatory T cells - Read more

AstraZeneca halts Ph1 trial of NT-125 T-cell receptor therapy for solid tumors amid portfolio reprioritization
Cell therapy, cancer, T-cell receptor therapy, solid tumors, strategic pipeline prioritization - Read more

THE BAD
Earnings & Finances

Novo Nordisk cuts 2025 sales forecast by 5% amid slowing Wegovy and Ozempic growth
GLP-1 agonist, diabetes, obesity, financial, revenue impact, competitive - Read more

THE BAD
Strategic Plans

Quoin Pharmaceuticals discontinues two assets to focus on lead Netherton syndrome program approaching FDA submission
Serine protease inhibitor, rare disease, strategic, operational, cost reduction - Read more

Merck & Co. plans $3B cost cuts to redirect funds toward 20+ new product launches
Oncology, monoclonal antibody, financial, cost reduction, strategic - Read more

THE UGLY
Politics & Policy

HHS Secretary Kennedy pledges to overhaul "broken" Vaccine Injury Compensation Program amid criticism
Vaccine policy, regulatory, public health, operational, competitive - Read more

THE UGLY
Regulatory

FDA vaccine office head Vinay Prasad resigns after just three months amid controversy
Gene therapy, vaccines, regulatory, leadership change, policy shift - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here